Methylphenidate prodrug

Drug Profile

Methylphenidate prodrug

Alternative Names: D-threo-methylphenidate prodrug - KemPharm; KP 415; KP 484; Methylphenidate-prodrug-KemPharm

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KemPharm
  • Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine release stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Attention-deficit hyperactivity disorder

Highest Development Phases

  • Phase I Attention-deficit hyperactivity disorder

Most Recent Events

  • 02 Nov 2017 US FDA approves IND application for KP 484 in Attention deficit hyperactivity disorder
  • 20 Sep 2017 KemPharma announces intention to submit NDA to the US FDA for KP 484 for Attention deficit hyperactivity disorder in 2019
  • 20 Sep 2017 KemPharm files an IND application with the FDA in USA for KP 484 for Attention deficit hyperactivity disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top